Pfizer halts Gleevec replacement trial after early success

02/2/2005 | iWon

Pfizer decided to stop the trial for its SU11248 drug for treating stomach cancer after the drug was proven effective by meeting its efficacy targets. SU11248 appears to be a viable replacement for Novartis' Gleevec, the current standard treatment that is ineffective in some patients. An analyst said the early success means Pfizer could receive approval as early as this year.

View Full Article in:

iWon

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX